Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | BRS3 | P32247 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 2/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL142826 | 0.88 | GHSR (0.39) | GHSRCYP17A1NAMPTBRS3MAPT | |
| SCHEMBL146430 | 0.86 | GHSR (0.41) | GHSRCYP17A1NAMPTBRS3RAB9A | |
| SCHEMBL8346749 | 0.84 | GHSR (0.47) | GHSRRAB9A | |
| SCHEMBL555073 | 0.82 | NAMPT (0.48) | CYP17A1NAMPTMAPTGSK3BRAB9A | |
| SCHEMBL8344329 | 0.81 | KMT2A (0.50) | GHSRRAB9A | |
| SCHEMBL31611248 | 0.80 | NAMPT (0.57) | GHSRNAMPTRAB9A | |
| SCHEMBL26318454 | 0.80 | NAMPT (0.57) | GHSRNAMPTRAB9A | |
| SCHEMBL8345080 | 0.80 | MEN1 (0.52) | GHSR | |
| SCHEMBL7484295 | 0.75 | NAMPT (0.43) | CYP17A1NAMPTRAB9AMAP4K1 | |
| SCHEMBL31654157 | 0.75 | FPR2 (0.54) | GHSRNAMPTBDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | CYP11B1 968/4885CYP11B2 1038/4885GHSR 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.